Cambrian’s ATX-304 pill makes cells burn more energy
Cambrian Bio took human data on the first AMPK Network Activator to ObesityWeek 2026, and its muscle-sparing claim rests on mice. Back in 2023, Cambrian CEO James Peyer told BioSpace that an AMPK-targeting drug could produce weight loss “without losing muscle or even gaining muscle.” He attached an

<p>Cambrian Bio took human data on the first AMPK Network Activator to ObesityWeek 2026, and its muscle-sparing claim rests on mice. Back in 2023, Cambrian CEO James Peyer told BioSpace that an AMPK-targeting drug could produce weight loss “without losing muscle or even gaining muscle.” He attached an </p>